University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flanders-Artois• Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois). • Consulting, Partnering & Fund Raising, Founder, Managing Director, NxR Biotechnologies, Switzerland.• Dr. Vertès is a strategy and business development consultant for cell therapeutic biotech companies, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, he has contributed to both industrial and pharmaceutical biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche). • Championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche’s global cell therapeutics strategy and implementation team resulting in Roche’s entry in 2010 in the field of regenerative medicine.• Member, Industry Committee-Europe, Tissue Engineering and Regenerative Medicine International Society• Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015). • Head of Operations & Strategy, Medicinal Sciences Division of R&D, Pfizer Inc.• Responsible for all cell & gene therapy products, as well as previously developing Pfizer’s Regenerative Medicine program.• PhD in Genetics from Harvard Medical School.• Adjunct faculty member at Northeastern University. Research Chemical/Biochemical Engineer, United States Department of Agriculture (USDA), Agricultural Research Service (ARS), National Center for Agricultural Utilization Research (NCAUR), Peoria, IL, USA.PhD (Chemical/Biological Engineering), PhD (Fermentation Technology)Fellow in American Institute of Chemical Engineers (AIChE), Society for Industrial Microbiology & Biotechnology (SIMB), and American Institute of Chemists (AIC).Co-Editor, Stem cells in Regenerative Medicine (Wiley, 2015)

• PART 1 Science1. Innovation S- Curves in Living Drugs Development and Their Commercialisation2. Development and Deployment of Gene Therapies: An ADA- SCID Case Study3. Therapeutic Potential of Cells of the Immune System4. T Cell Engineering and the Rise of CAR- T Cell Therapies5. Harnessing Natural Killer Cells’ Killing Function in Cancer6. Pluripotent Stem Cell–Derived Islet Replacement Therapy for Diabetes7. Harnessing in Silico Technologies to Develop and Augment Second- Generation Cell- Based Therapies8. Second Generation Genome Editing Technologies in Drug Discovery9. The Next Wave: Tissue Replacement and Organ Replacement10. Combining Stem Cells and Materials for Nerve Tissue RegenerationPART 2 Translation11. Gene Therapy Clinical Trials: Past, Present and Future12. CAR-T Cell Clinical Trials Experience – Past, Present and Future 13. T Cell Receptor Engineered T Cell Therapy in Oncology14. Cytotherapy Clinical Trials in Genetic Disorders of the Blood and Options for ReimbursementPART 3 The Next Frontier15.Mesenchymal Stromal Cell Therapies – The Next Frontiers16. Regenerative Medicine and Ageing: Is Senescence Reprogrammable?17. Deciphering the Systems Architecture of the Brain Using Molecular Can Openers18. Harnessing the Therapeutic Potential of Dendritic Cells19. Brief Overview of Chimeric Antigen Receptor–Mediated Immunotherapy for　Glioblastoma Multiforme20. Combination Therapies in Solid Tumour OncologyPART 4 Perspectives21. Gene- Editing Technologies in Adoptive T Cell Therapy for Cancer: An Ethical Analysis22. Decisions in the Development Lifecycle of Cell and Gene Therapies23 CAR- T: From Concepts to Products – Now What?24. Strategic Alliances in Cytotherapies and Gene Therapies: Funding the New Wave of Cell Therapeutics25. The Role of Governments in the Commercial Emergence of Radical Innovation: The Case of the United Kingdom26. Patenting Trends in Chimeric Antigen Receptor Technologies27. Reimbursement and Payment Models for Therapies With Transformative and Curative Intent28. Commercialising CAR- T Therapies: The Evolution of a Revolution29. Will You Move the Needle of Medicine?

University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flanders-Artois• Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois). • Consulting, Partnering & Fund Raising, Founder, Managing Director, NxR Biotechnologies, Switzerland.• Dr. Vertès is a strategy and business development consultant for cell therapeutic biotech companies, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, he has contributed to both industrial and pharmaceutical biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche). • Championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche’s global cell therapeutics strategy and implementation team resulting in Roche’s entry in 2010 in the field of regenerative medicine.• Member, Industry Committee-Europe, Tissue Engineering and Regenerative Medicine International Society• Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015). • Head of Operations & Strategy, Medicinal Sciences Division of R&D, Pfizer Inc.• Responsible for all cell & gene therapy products, as well as previously developing Pfizer’s Regenerative Medicine program.• PhD in Genetics from Harvard Medical School.• Adjunct faculty member at Northeastern University. Research Chemical/Biochemical Engineer, United States Department of Agriculture (USDA), Agricultural Research Service (ARS), National Center for Agricultural Utilization Research (NCAUR), Peoria, IL, USA.PhD (Chemical/Biological Engineering), PhD (Fermentation Technology)Fellow in American Institute of Chemical Engineers (AIChE), Society for Industrial Microbiology & Biotechnology (SIMB), and American Institute of Chemists (AIC).Co-Editor, Stem cells in Regenerative Medicine (Wiley, 2015)

• PART 1 Science1. Innovation S- Curves in Living Drugs Development and Their Commercialisation2. Development and Deployment of Gene Therapies: An ADA- SCID Case Study3. Therapeutic Potential of Cells of the Immune System4. T Cell Engineering and the Rise of CAR- T Cell Therapies5. Harnessing Natural Killer Cells’ Killing Function in Cancer6. Pluripotent Stem Cell–Derived Islet Replacement Therapy for Diabetes7. Harnessing in Silico Technologies to Develop and Augment Second- Generation Cell- Based Therapies8. Second Generation Genome Editing Technologies in Drug Discovery9. The Next Wave: Tissue Replacement and Organ Replacement10. Combining Stem Cells and Materials for Nerve Tissue RegenerationPART 2 Translation11. Gene Therapy Clinical Trials: Past, Present and Future12. CAR-T Cell Clinical Trials Experience – Past, Present and Future 13. T Cell Receptor Engineered T Cell Therapy in Oncology14. Cytotherapy Clinical Trials in Genetic Disorders of the Blood and Options for ReimbursementPART 3 The Next Frontier15.Mesenchymal Stromal Cell Therapies – The Next Frontiers16. Regenerative Medicine and Ageing: Is Senescence Reprogrammable?17. Deciphering the Systems Architecture of the Brain Using Molecular Can Openers18. Harnessing the Therapeutic Potential of Dendritic Cells19. Brief Overview of Chimeric Antigen Receptor–Mediated Immunotherapy for　Glioblastoma Multiforme20. Combination Therapies in Solid Tumour OncologyPART 4 Perspectives21. Gene- Editing Technologies in Adoptive T Cell Therapy for Cancer: An Ethical Analysis22. Decisions in the Development Lifecycle of Cell and Gene Therapies23 CAR- T: From Concepts to Products – Now What?24. Strategic Alliances in Cytotherapies and Gene Therapies: Funding the New Wave of Cell Therapeutics25. The Role of Governments in the Commercial Emergence of Radical Innovation: The Case of the United Kingdom26. Patenting Trends in Chimeric Antigen Receptor Technologies27. Reimbursement and Payment Models for Therapies With Transformative and Curative Intent28. Commercialising CAR- T Therapies: The Evolution of a Revolution29. Will You Move the Needle of Medicine?

University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flanders-Artois• Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois). • Consulting, Partnering & Fund Raising, Founder, Managing Director, NxR Biotechnologies, Switzerland.• Dr. Vertès is a strategy and business development consultant for cell therapeutic biotech companies, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, he has contributed to both industrial and pharmaceutical biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche). • Championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche’s global cell therapeutics strategy and implementation team resulting in Roche’s entry in 2010 in the field of regenerative medicine.• Member, Industry Committee-Europe, Tissue Engineering and Regenerative Medicine International Society• Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015). • Head of Operations & Strategy, Medicinal Sciences Division of R&D, Pfizer Inc.• Responsible for all cell & gene therapy products, as well as previously developing Pfizer’s Regenerative Medicine program.• PhD in Genetics from Harvard Medical School.• Adjunct faculty member at Northeastern University. Research Chemical/Biochemical Engineer, United States Department of Agriculture (USDA), Agricultural Research Service (ARS), National Center for Agricultural Utilization Research (NCAUR), Peoria, IL, USA.PhD (Chemical/Biological Engineering), PhD (Fermentation Technology)Fellow in American Institute of Chemical Engineers (AIChE), Society for Industrial Microbiology & Biotechnology (SIMB), and American Institute of Chemists (AIC).Co-Editor, Stem cells in Regenerative Medicine (Wiley, 2015)

• PART 1 Science1. Innovation S- Curves in Living Drugs Development and Their Commercialisation2. Development and Deployment of Gene Therapies: An ADA- SCID Case Study3. Therapeutic Potential of Cells of the Immune System4. T Cell Engineering and the Rise of CAR- T Cell Therapies5. Harnessing Natural Killer Cells’ Killing Function in Cancer6. Pluripotent Stem Cell–Derived Islet Replacement Therapy for Diabetes7. Harnessing in Silico Technologies to Develop and Augment Second- Generation Cell- Based Therapies8. Second Generation Genome Editing Technologies in Drug Discovery9. The Next Wave: Tissue Replacement and Organ Replacement10. Combining Stem Cells and Materials for Nerve Tissue RegenerationPART 2 Translation11. Gene Therapy Clinical Trials: Past, Present and Future12. CAR-T Cell Clinical Trials Experience – Past, Present and Future 13. T Cell Receptor Engineered T Cell Therapy in Oncology14. Cytotherapy Clinical Trials in Genetic Disorders of the Blood and Options for ReimbursementPART 3 The Next Frontier15.Mesenchymal Stromal Cell Therapies – The Next Frontiers16. Regenerative Medicine and Ageing: Is Senescence Reprogrammable?17. Deciphering the Systems Architecture of the Brain Using Molecular Can Openers18. Harnessing the Therapeutic Potential of Dendritic Cells19. Brief Overview of Chimeric Antigen Receptor–Mediated Immunotherapy for　Glioblastoma Multiforme20. Combination Therapies in Solid Tumour OncologyPART 4 Perspectives21. Gene- Editing Technologies in Adoptive T Cell Therapy for Cancer: An Ethical Analysis22. Decisions in the Development Lifecycle of Cell and Gene Therapies23 CAR- T: From Concepts to Products – Now What?24. Strategic Alliances in Cytotherapies and Gene Therapies: Funding the New Wave of Cell Therapeutics25. The Role of Governments in the Commercial Emergence of Radical Innovation: The Case of the United Kingdom26. Patenting Trends in Chimeric Antigen Receptor Technologies27. Reimbursement and Payment Models for Therapies With Transformative and Curative Intent28. Commercialising CAR- T Therapies: The Evolution of a Revolution29. Will You Move the Needle of Medicine?